Insomnia, a common and debilitating condition, affects millions of people worldwide, causing significant distress and impacting daily functioning. A recent study published in Sleep Medicine has shown that daridorexant, Idorsia’s dual orexin receptor antagonist, improves sleep maintenance throughout the entire night and reduces morning sleepiness, thereby enhancing daytime functioning.
Chronic Insomnia: A Growing Concern
Chronic insomnia is defined as difficulty initiating and/or maintaining sleep at least three times a week for a minimum of three months, resulting in a significant negative impact on daytime functioning. This condition is characterized by overactive wake signaling, leading to inadequate sleep quality and persistent sleep-wake cycles.
Daridorexant: A Novel Approach to Insomnia Treatment
Daridorexant, commercially available as QUVIVIQ, is a dual orexin receptor antagonist that blocks the binding of wake-promoting orexin neuropeptides. By selectively targeting the orexin receptors, daridorexant reduces the overactive wake drive associated with insomnia, leading to improved sleep quality and reduced morning sleepiness.
Key Findings of the Study
The Phase 3 studies analyzed data from 930 patients with insomnia disorder, demonstrating that daridorexant significantly reduced polysomnography-determined wake after sleep onset (WASO) versus placebo. The study also showed that daridorexant improved daytime alertness, ability to function, and reduced next-morning sleepiness.
- Reduced WASO in each 2-hour quarter (Q) of the night
- Improved daytime alertness, ability to function, and reduced next-morning sleepiness
- Dose-dependent effects, with a greater effect seen in the 50 mg group
Benefits of Daridorexant
Daridorexant offers several advantages over existing treatments for insomnia, including:
- Improved sleep maintenance throughout the entire night
- Reduced morning sleepiness without residual effects
- Enhanced daytime functioning and alertness
Expert Insights
Yves Dauvilliers, MD, PhD, Professor of Neurology and Physiology, and Head of the clinical and research activity of the sleep laboratory at the University of Montpellier, commented:
“Reducing wakefulness throughout the night without next-day residual effects are two essential characteristics of the ideal sleeping pill. Daridorexant works throughout the entire night, especially in the second half of the night when patients need it the most. Remarkably, it achieves this without residual drug effects and even improves morning sleepiness.”
Daridorexant is commercially available in several countries, including the US, Germany, Italy, Switzerland, Spain, the UK, Canada, Austria, France, Sweden, and Japan. Idorsia is reaching out for more, with a passion for science, opportunities, and helping more patients.
Dauvilliers Y et al. Sleep Medicine. 2025. doi: 10.1016/j.sleep.2025.106523
Mignot E et al. Lancet Neurol. 2022;21(2):125-139. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed., Text Revision. American Psychiatric Publishing. 2022.
Idorsia Ltd is a leading biopharmaceutical company focused on discovering, developing, and commercializing transformative medicines. The company is headquartered near Basel, Switzerland, and has a highly experienced team of professionals covering all disciplines from bench to bedside.
Related Articles
